<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02167711</url>
  </required_header>
  <id_info>
    <org_study_id>BTC001</org_study_id>
    <nct_id>NCT02167711</nct_id>
  </id_info>
  <brief_title>Treatment for Bile Duct Cancer in the Liver</brief_title>
  <official_title>Selective Internal Radiation Therapy With Yttrium-90 Resin Microspheres Followed by Gemcitabine Plus Cisplatin for Intra-hepatic Cholangiocarcinoma: A Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current standard treatment of inoperable intrahepatic cholangiocarcinoma (bile duct&#xD;
      cancer in the liver) is chemotherapy, which is of limited efficacy. The use of selective&#xD;
      internal radiotherapy treatment (SIRT-Y90) is proven efficacious in patients with&#xD;
      intra-heptic tumor. Previous experience with SIRT is safe in patients with intrahepatic&#xD;
      cholangiocarcinoma. This study aims to study the benefits of sequential administration of&#xD;
      SIRT followed by standard chemotherapy for treatment of inoperable intrahepatic&#xD;
      cholangiocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2014</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological response</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration between timing of chemotherapy and SIRT-Y90</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and severity of toxicities</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serological response in CA 19.9</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Cholangio Carcinoma</condition>
  <arm_group>
    <arm_group_label>SIRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SIRT Yttrium-90</intervention_name>
    <arm_group_label>SIRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt;18 years&#xD;
&#xD;
          -  Histological or cytological diagnosis of cholangiocarcinoma&#xD;
&#xD;
          -  Disease not amenable to surgery&#xD;
&#xD;
          -  Predominant disease load in the liver (in case of extra-hepatic involvement, only&#xD;
             patients with lymph nodes metastases are allowed)&#xD;
&#xD;
          -  Naïve to locoregional or systemic treatment (but patients who develop recurrent&#xD;
             disease after surgery are suitable)&#xD;
&#xD;
          -  ECOG PS 0-1&#xD;
&#xD;
          -  At least one measurable disease lesion according to RECIST v 1.1&#xD;
&#xD;
          -  Life expectancy of 12 weeks or longer&#xD;
&#xD;
          -  Adequate hematological, renal and hepatic function&#xD;
&#xD;
          -  Platelet ≥100 x 109&#xD;
&#xD;
          -  ANC ≥ 1.5 x 109&#xD;
&#xD;
          -  Bilirubin ≤ 30µmol/L&#xD;
&#xD;
          -  Albumin ≥ 30g/L&#xD;
&#xD;
          -  ALT ≤ 3 ULN&#xD;
&#xD;
          -  INR ≤ 1.5&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior malignancy except cervical carcinoma-in-situ or treated basal cell carcinoma.&#xD;
             Any cancers treated curatively &gt; 5 years prior to study entry are permitted.&#xD;
&#xD;
          -  Patients with extra-hepatic disease other than regional lymph node metastases.&#xD;
&#xD;
          -  Evidence of ascites or cirrhosis, as determined by clinical or radiologic assessment&#xD;
&#xD;
          -  Biliary obstruction with no possibility of drainage&#xD;
&#xD;
          -  Non-malignant disease that would render the patient unsuitable for treatment according&#xD;
             to the protocol&#xD;
&#xD;
          -  Prior treatment of chemotherapy for the cholangiocarcinoma&#xD;
&#xD;
          -  Prior radiation therapy to the upper abdomen&#xD;
&#xD;
          -  Complete thrombosis of the main portal vein&#xD;
&#xD;
          -  Tumor volume &gt; 50% of the normal liver volume&#xD;
&#xD;
          -  Allergy to non-ionic contrast agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen L Chan, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Oncology, The Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephen L Chan, FRCP</last_name>
    <phone>35052166</phone>
    <email>l_chan@clo.cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jane Koh, RN</last_name>
    <phone>35051142</phone>
    <email>jane@clo.cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Clinical Oncology, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen L Chan, FRCP</last_name>
      <phone>35052166</phone>
      <email>l_chan@clo.cuhk.edu.hk</email>
    </contact>
    <contact_backup>
      <last_name>Jane Koh, RN</last_name>
      <phone>35051142</phone>
      <email>jane@clo.cuhk.edu.hk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 17, 2014</study_first_submitted>
  <study_first_submitted_qc>June 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2014</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>CCTU</investigator_full_name>
    <investigator_title>Comprehensive Clinical Trial Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

